englumafusp alfa + glofitamab

**Englumafusp alfa + glofitamab** is an investigational intravenous fixed-duration combination therapy under clinical development for relapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL), particularly aggressive subtypes such as diffuse large B-cell lymphoma. Englmafusp alfa is an antibody-like fusion protein targeting CD19 on B cells and 4-1BB (CD137) on T and immune effector cells, acting as a 4-1BB agonist and requiring CD19 crosslinking for activity. This costimulates and boosts anti-tumor T cell responses. Glofitamab is a CD20xCD3 bispecific monoclonal antibody that redirects T cells to CD20+ B cells, inducing tumor cell lysis and 4-1BB upregulation. The combination is designed to provide synergistic and prolonged immune activation, with evidence of robust peripheral expansion of activated and memory T cells, effectiveness in less inflamed lymphoma settings, and manageable safety/tolerability in early-phase clinical trials. Both drugs are administered intravenously, typically following pretreatment with obinutuzumab. Studies are sponsored by and the agents are developed by Roche.

Other names

englumafusp alfa + glofitamab